All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Visual abstract | Auto-HSCT after a rituximab/ibrutinib/Ara-c containing induction in generalized mantle cell lymphoma: TRIANGLE trial
Bookmark this article
The Lymphoma Hub is pleased to present a visual abstract summarizing results from the phase III TRIANGLE trial (NCT02858258) assessing the safety and efficacy of the addition of ibrutinib, a Bruton’s tyrosine kinase inhibitor, to standard immunochemotherapy with or without autologous hematopoietic stem cell transplantation (auto-HSCT) in younger patients with mantle cell lymphoma. Results from this trial were published by Dreyling et al.1 in The Lancet.
The addition of ibrutinib to standard immunochemotherapy improved outcomes; however, toxicity was increased when ibrutinib was given after auto-HSCT.1 Whether auto-HSCT is beneficial with ibrutinib-based treatment is yet to be determined.1
- Dreyling M, Doorduijn J, Giné E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. 2024. Online ahead of print. DOI: 10.1016/S0140-6736(24)00184-3.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
44 votes - 79 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox